Abstract |
Spiroplatin was investigated in a multicenter phase II study, during which the drug was given over 4 h. 64 Patients with nine different solid tumors received 141 cycles of spiroplatin at a dose of 30 mg/m2 every 3 weeks. Most important side effects included nausea, vomiting, myelosuppression, and renal toxicity. Four of 11 evaluable patients with prior cisplatin developed increases in serum creatinine (3 transient, 1 died of renal failure). Of 51 patients without prior cisplatin 2 had a transient increase in serum creatinine levels, and 2 showed persistent changes, in 1 of them leading to hemodialysis. Pre- and posthydration did not reduce drug-induced nephrotoxicity. Only 3 patients showed a response; 1 with renal cell carcinoma, 1 with ovarian carcinoma, and 1 with malignant melanoma. Based on the absence of striking antitumor activity and on the presence of severe unpredictable renal toxicity, the study was stopped prematurely.
|
Authors | B C Tanis, J B Vermorken, W W ten Bokkel Huinink, A T van Oosterom, T A Splinter, K J Vendrik, D T Sleijfer, M E van der Burg, E van der Putten, H M Pinedo |
Journal | Oncology
(Oncology)
Vol. 49
Issue 2
Pg. 99-103
( 1992)
ISSN: 0030-2414 [Print] Switzerland |
PMID | 1574259
(Publication Type: Clinical Trial, Journal Article, Multicenter Study)
|
Chemical References |
- Antineoplastic Agents
- Organoplatinum Compounds
- spiroplatin
|
Topics |
- Antineoplastic Agents
(adverse effects)
- Drug Evaluation
- Humans
- Kidney Diseases
(chemically induced)
- Leukocyte Count
(drug effects)
- Neoplasms
(drug therapy)
- Organoplatinum Compounds
(adverse effects, therapeutic use)
- Platelet Count
(drug effects)
|